Ovid therapeutics inc. (OVID)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating expenses:
Research and development

14,625

12,105

11,597

9,117

9,337

8,654

8,544

8,116

8,474

6,713

5,899

6,074

31,284

3,990

2,698

1,770

1,126

General and administrative

5,669

5,162

5,168

4,204

4,716

4,461

4,631

5,093

4,955

4,334

3,509

4,213

2,977

-

3,116

3,646

-

Selling, general and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,587

Total operating expenses

20,294

17,267

16,765

13,322

14,053

13,116

13,175

13,209

13,429

11,048

9,409

10,288

34,262

7,588

5,814

5,416

3,714

Loss from operations

-20,294

-17,267

-16,765

-13,322

-14,053

-13,116

-13,175

-13,209

-13,429

-11,048

-9,409

-10,288

-34,262

-

-5,814

-5,416

-

Interest income

264

299

131

264

253

216

213

274

247

87

50

39

23

27

29

31

32

Loss before income tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,682

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net loss

-20,030

-16,968

-16,634

-13,057

-13,800

-12,900

-12,961

-12,935

-13,182

-10,960

-9,358

-10,248

-34,238

-7,561

-5,785

-5,385

-3,682

Net loss attributable to common stockholders

-20,030

-16,968

-16,634

-13,057

-13,800

-12,900

-12,961

-12,935

-13,182

-10,960

-9,358

-10,248

-34,238

-7,561

-5,785

-5,385

-3,682

Net loss per share, basic and diluted

-

-0.35

-

-

-

-0.52

-

-

-

1.08

-0.38

-0.57

-3.48

-0.77

-0.59

-0.55

-0.37

Weighted-average shares outstanding basic and diluted

-

-

-

-

-

-

-

-

-

24,824

24,601

18,112

9,838

9,838

9,838

9,838

9,838

Common Stock [Member]
Net loss per share, basic and diluted

-0.37

-0.31

-0.43

-0.34

-0.46

-0.51

-0.53

-0.53

-0.54

-

-

-

-

-

-

-

-

Weighted-average shares outstanding basic and diluted

54,715

49,341

38,504

38,693

30,329

24,654

24,634

24,625

24,609

-

-

-

-

-

-

-

-